Skip to main content

Advertisement

ADVERTISEMENT

Clinical Images

Sealing a Multilobe Left Atrial Appendage With Kissing-Watchman Technique

Jie Zeng, MD, Cong Lu, MD, Hui Huang

Division of Cardiology, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China

A 72-year-old man was admitted because of persistent atrial fibrillation after suffering a stroke 4 months prior. CHA2DS2-VASc score was 4 and HAS-BLED score was 2. Considering the potentially life-threatening bleeding complications, the patient chose left atrial appendage (LAA) closure instead of long-term anticoagulation therapy.  

Transesophageal echocardiography (TEE) showed a large-ostium, 26 x 31 mm LAA; angiography showed a cactus morphology with 3 early outgoing lobes (Figure 1A). A significant residual leak persisted after we chose the upper lobe as the landing zone for a 33 mm Watchman device (Boston Scientific). We then tried to repeatedly deploy the Watchman in the medium or lower lobe zones, but significant residual leakage still persisted. Therefore, we planned to close the LAA with a kissing-Watchman technique. First, a 27 mm Watchman was anchored in the upper lobe, and pull test was performed to ensure stabilization. Transesophageal echocardiography (TEE) showed a 16 mm residual leakage in the lower lobe, so a 21 mm Watchman was placed next to the first device (Figure 1B). The tug-test was performed on both devices; TEE showed no residual leaks. Postprocedure TEE 2 months later showed a 2 mm residual leak between the devices (Figure 1C), while TEE at 16-month follow-up showed no device-related thrombus and no residual leakage (Figure 1D). Warfarin was prescribed for the first 2 months, and dual-antiplatelet therapy (aspirin 100 mg/day and clopidogrel 75 mg/day) was given until 12 months; aspirin 100 mg/day was then prescribed indefinitely. 

View the accompanying video series here: 

https://bit.ly/2J1CbVv

Reprinted with permission from J INVASIVE CARDIOL. 2020;32(1):E17.

Disclosures: The authors report no conflicts of interest regarding the content herein.


Advertisement

Advertisement

Advertisement